Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 56,400 shares, a growth of 32.4% from the August 15th total of 42,600 shares. Based on an average trading volume of 29,900 shares, the short-interest ratio is presently 1.9 days.
Bioasis Technologies Stock Performance
BIOAF remained flat at $0.13 during midday trading on Friday. The firm's fifty day moving average is $0.12 and its 200 day moving average is $0.16. Bioasis Technologies has a 52-week low of $0.10 and a 52-week high of $0.28.
Get
Bioasis Technologies alerts:
About Bioasis Technologies
(Get Rating)
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 56,400 shares, a growth of 32.4% from the August 15th total of 42,600 shares. Based on an average trading volume of 29,900 shares, the short-interest ratio is presently 1.9 days.
生物绿洲科技公司(BiOASIS Technologies Inc.)是8月份空头股数大幅增长的目标。截至8月31日，空头股数共有56,400股，较8月15日的42,600股增长32.4%。以平均成交量29,900股计算，目前短息比率为1.9天。
Bioasis Technologies Stock Performance
BIOAF remained flat at $0.13 during midday trading on Friday. The firm's fifty day moving average is $0.12 and its 200 day moving average is $0.16. Bioasis Technologies has a 52-week low of $0.10 and a 52-week high of $0.28.
周五午盘，BIOAF持平于0.13美元。该公司的50日移动均线切入位为0.12美元，200日移动均线切入位为0.16美元。BiOasis Technologies的52周低点为0.10美元，52周高位为0.28美元。
Get
Bioasis Technologies
alerts:
About Bioasis Technologies
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
BiOASIS技术公司是一家处于发展阶段的生物制药公司，致力于神经疾病和障碍的诊断和治疗产品的研究和开发。它正在开发xB3，这是一种通过血脑屏障(BBB)运输治疗剂的平台技术；以及治疗中枢神经系统疾病(CNS)，包括脑癌，以及代谢和神经退行性疾病。
Featured Stories
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- 免费获取StockNews.com关于BiOASIS技术的研究报告(BIOAF)
- 第四季度值得考虑的3家银行
- 股市：红海中的三座强国
- MarketBeat：回顾一周9/12-9/16
- 没有人告诉这三只股票这是下跌的一周
- 有什么办法可以治愈Teladoc股票的问题吗？
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《BiOASIS技术日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对BiOasis Technologies及相关公司的评级的每日摘要。
